These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30962339)

  • 1. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.
    Bhavnani SM; Hammel JP; Lakota EA; Safir MC; VanScoy BD; Nagira Y; Rubino CM; Sato N; Koresawa T; Kondo K; Ambrose PG
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32661000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
    Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
    Jones RN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S81-7. PubMed ID: 20597676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
    J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against
    Ji XW; Xue F; Kang ZS; Zhong W; Kuan IH; Yang XP; Zhu X; Li Y; Lv Y
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
    Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
    J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
    Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP
    Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
    Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the prevalence of pathogens causing hospital-acquired bacterial pneumonia and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity-score-matched study.
    Choi MH; Kim D; Lee KH; Cho JH; Jeong SH
    Int J Antimicrob Agents; 2023 Sep; 62(3):106886. PubMed ID: 37343808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
    Kidd JM; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2018 Mar; 19(4):397-408. PubMed ID: 29411661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
    Talbot GH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.